L19: AML + MDS notes:
	- AML risks:
		- topoIIi (del 11q23) + akylators (del 5+7)
		- radiation/solvents
		- downs, li fraumeni (p53), fanconi's anemia
	- bad muts: tp53, SF3B1, inv(3), BCR-ABL1
	- intermediate muts: FLT3, t(9, 11), 
	- good muts: t(8, 21), inv(16), NPM1 w/o FLT3
		- gemtuzumab: CD33
		- FLT3 muts: midostaurin, gilteritinib
		- low risk t(8, 21), inv(16): 7+3

	- APL: 
		- t(15, 17)
	- MDS:
		- 5q- syndrome:


L20 ALL + CLL:
	- ALL:
		- worse prognosis:
			- t(9, 22)
		- good prognosis:
			- t(12, 21)
		- T cell - ALL: mediastinal mass, SVC-like syndrome
		- markers:
			- TdT+: blast
			- CD10: B-cell lymphoblast

	- CLL:
		- richter transformation: rare transform to DLBCL
		- mutatated IGHV -> more differentiated -> better prognosis
		- markers:
			- CD5, CD19/20/23
		- prognosis:
			- good: 13q-
			- bad: 17p-


L21 B-cell lymphoma:
	- diffuse large N cell lymphoma:
		- germinal center
		- prognosis:
			- aggressive
			- fatal within months
			- 65% cure rate
		- associated with HIV
		- pathology:
			- 4-5x size of lymphocyte
			- diffuse growth pattern
			- markers: CD19+, CD20+
	
	- burkitt's lymphoma:
		- germinal center
		- pathogenesis:
			- c-myc translocation with heavy chain Ig, t(8, 14)
		- pathology: CD20+ starry sky, tingible body macrophages
	
	- mantle cell lymphoma:
		- aggresive:
		- pathology:
			- small lymphocytes
			- nodular to diffuse
			- markers: cyclin D1+, CD20+
			- t(11, 14): cyclin D1:IgH

	- follicular lymphoma:
		- pathology:
			- markers: BCL2+, CD20+

		- pathogenesis:
			- t(14, 18): IgH + BCL-2

	- marginal zone lymphoma:
		- pathogenesis:
			- t(11, 18): API2/MALT1



L23 Hodgkins + T cell lymphoma:
	- hodgkins:
		- CD20- B-cell lymphoma
		- types:
			- nodular sclerosis: most common
			- mixed cellularity: HIV, eosinophilia
			- lymphocyte rich: best prognosis
			- lymphocyte depleted: worst prognosis

	- T-cell lymphoma:
		- rare/heterogenous

		- cutaneous T cell lymphoma (mycosis fungoides):
			- indolent
			- stages:
				- patch-plaque stage
				- tumor
				- lymph node involvement
				- sezary syndrome: leukemic involvement

			- pathology:
				- Pautrier microabscess: intraepidermal neoplastic cell aggregates
				- sezary cell: CD4+ + "cerebriform nuclei"

		- peripheral T cell lymphoma: PTCL-NOS:

		- anaplastic large T cell lymphoma:
			- ALK+: younger, t(2, 5) -> better prognosis
			- pathology: horeshoe shaped nuclei

		- HTLV-1 / adult T-cell leukemia/lymphoma (ATLL):
			- pathology: flower cell
			- markers: CD4+, CD25+, sometimes CD30+
			- pathogeneis:
				- driven by HTLV-1
				- long latency
			- epidimiology:
				- endemic to africa, japan, and caribbean
			- sx:
				- hypercalcemia
				- lytic bone lesions
				- CNS lesions
				- rash
				- lymphadenopathy


L24 multiple myeloma:
	- multiple myeloma:

	- monoclonal gammopathy of undetermined significance (MGUS):
		- 1% per yr -> MM
		- tx: observe 6-12 mos

	– smoldering multiple myeloma (SMM):
		- M-spike > 3
		- BM clonal plasma >= 10%
		- 50% at 5 yr -> MM
		- observe every 3 months

	– waldenstrom’s macroglobulinemia:
		- rare
		- lymphoplasmacytic cells
		- MYD88 mutation
		- M protein: IgM
		- symptoms:
			- hyperviscosity: blurry vision, headache, vertigo, stroke, etc
			- oronasal bleeding
			- hepatosplenomegaly, lymphadenopathy
			- anemia, weakness
			- neuropathy
			- raynaud phenomenon

	– AL amyloidosis:

L25 CML + NPMs:
	- CML:
		- pathology:
			- basophilia, thrombocytosis
			- peripheral blood: looks like bone marrow
			- bone marrow: hypercellular, increased myeloid:erythroid
		- t(9, 22):

	- polycythemia vera (PV):
		- JAK2 V617F:

		- pathology:
			- bone marrow: moderate/marked hypercellularity
			- large clustered megakaryocytes
			- decreased iron stores
			- increased reticulin fibers
		- 3% mortality each year

	- essential thrombocytosis (ET):
		- course:
			- 1% untreated -> AML
			- 4-8% -> PMF

	- primary myelofibrosis (PMF):
		- pathology:
			- BM fibrosis
			- bizarre megakaryocyte hyperplasia
			- extramedullary hematopoiesis
				- in spleen, liver, etc
			- teardrop RBCs
			- blood looks like marrow	

		- course:
			- life expectancy: variable ~5 years
			- risks:
				- inv(3), del 5/7, +8, del 11q23
			- 10-15% -> AML